Cargando…

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study

AIMS: To investigate changes in glycated hemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) in type 2 diabetes (T2D) primary care patients initiating dapagliflozin treatment. METHODS: T2D patients who started dapagliflozin in 985 general and 32 diabetologist practices (Disease A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheerer, Markus F, Rist, Roland, Proske, Orm, Meng, Annika, Kostev, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096728/ https://www.ncbi.nlm.nih.gov/pubmed/27822077 http://dx.doi.org/10.2147/DMSO.S116243

Ejemplares similares

Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study
por: Kostev, Karel, et al.
Publicado: (2017)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients
por: Wang, Dong-Dong, et al.
Publicado: (2023)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2012)

The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes
por: Takao, Toshiko, et al.
Publicado: (2015)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus
por: Parkinson, Joanna, et al.
Publicado: (2019)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Assessment of subclinical left ventricular systolic dysfunction in patients with type 2 diabetes: Relationship with HbA1c and microvascular complications
por: Chen, Yanyan, et al.
Publicado: (2023)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Simulation of a computed HbA(1c) using a weighted average glucose
por: Boutayeb, W., et al.
Publicado: (2016)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Differential Thermal Stability and Oxidative Vulnerability of the Hemoglobin Variants, HbA(2) and HbE
por: Chakrabarti, Abhijit, et al.
Publicado: (2013)

Significantly High HbA(1c) in Diabetic Patient with Hb J: Case Report
por: Wan Nik, Wan Nor Fazila Hafizan, et al.
Publicado: (2022)

Low HbA2 Level in β-Thalassemia Trait
por: ÖZSOYLU, Şinasi
Publicado: (2013)

HbA(1c) measurement and relationship to incident stroke
por: Robson, R., et al.
Publicado: (2016)

Very low HbA1C, is it a problem?
por: Joob, Beuy, et al.
Publicado: (2018)

Engineering of the endogenous HBD promoter increases HbA2
por: Boontanrart, Mandy Y, et al.
Publicado: (2023)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
por: Choy, S, et al.
Publicado: (2015)

Feasibility study of portable technology for weight loss and HbA1c control in type 2 diabetes
por: Bentley, Claire L., et al.
Publicado: (2016)

Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy(†)
por: Fujita, Naotaka, et al.
Publicado: (2011)

HbA1c, blood pressure, and cholesterol control in adults with diabetes: A report card for Kuwait
por: Alkandari, Abdullah, et al.
Publicado: (2022)

Association of visit-to-visit HbA1c variability with cardiovascular diseases in type 2 diabetes within or outside the target range of HbA1c
por: Sun, Bao, et al.
Publicado: (2022)

An Evaluation of Point-of-Care HbA1c, HbA1c Home Kits, and Glucose Management Indicator: Potential Solutions for Telehealth Glycemic Assessments
por: Zaharieva, Dessi P., et al.
Publicado: (2022)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

Association of Diabetes and HbA(1c) Levels With Gastrointestinal Manifestations
por: Tseng, Ping-Huei, et al.
Publicado: (2012)

An Emerging Diabetes Mellitus Diagnosis Modality: HbA(1c)
por: Seo, Hyun-Ae, et al.
Publicado: (2012)

The Utility of HbA1c as a Diagnostic Criterion of Diabetes
por: Kim, Hee-Jung, et al.
Publicado: (2011)

The Importance of HbA1c Control in Patients with Subclinical Hypothyroidism
por: Billic-Komarica, Edina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rnqac464siqeb34ikrcar3anll